Evidence map›Paper›PMID 42015218›Full record

ArticleCardiovascular diabetology2026

GULP1 protects against diabetic cardiomyopathy through IKIP/NF-κB-dependent improvement of mitochondrial function.

Meng-Yuan Jiang, Xiao-Hua Zhang, Huan-Le Zhang, Yue Hou, Mei-Ying Qi, Yi-Xuan Zuo, Chuang Sun, Xin-Chun Dai, Ning-Ning Zhang, Tian-Qi Chen and 8 more

Abstract read
In one paragraph

Article in Cardiovascular diabetology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Meng-Yuan Jiang *Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Xiao-Hua Zhang *Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Huan-Le Zhang *Department of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Yue HouThe Analysis & Testing Laboratory for Life Sciences and Medicine, Air Force Medical University, Xi'an, 710032, China.
Mei-Ying QiSchool of Medicine, Northwest University, 229 Taibai North Road, Xi'an, 710069, China.
Yi-Xuan ZuoDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Chuang SunDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Xin-Chun DaiDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Ning-Ning ZhangDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Tian-Qi ChenDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Yan ZhangDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Wan-Rong ManDepartment of Critical Care Medicine, General Hospital of Western Theater Command, Chengdu, 610083, China.
Cong-Ye LiDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Jie LinDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Wen GeDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Li-Yu YangDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China.
Xing QinDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China. bravoqx@126.com.
Dong-Dong SunDepartment of Cardiology, Xijing Hospital, Air Force Medical University, Xi'an, 710032, China. wintersun3@fmmu.edu.cn.

Funding

Key logistic research projects BKJWS221J004Shaanxi Provincial Innovation Capacity Enhancement Program 2023-CX-PT-33Shaanxi Provincial Science and Technology Innovation Team 2024RS-CXTD-78the National Natural Science Foundation of China 82470358, 82200419Xi'an Young and Middle-Aged Leading Talents Program in Technological Innovation 25ZQRC00024Xijing Hospital Research Promotion Program XJZT24CZ13, XJZT24JC36, XJZT24LY38, LHJJ2023-YX05, XJZT25CX47, XJZT25QN24
6 · The paper itself

Abstract

backgroundMitochondrial structural abnormalities and impaired energy metabolism are recognized hallmarks of diabetic cardiomyopathy (DCM). GULP1 (PTB-domain engulfment adapter protein 1, also known as CED-6) is a cytoplasmic adaptor protein containing a phosphotyrosine-binding domain. GULP1 has been implicated in metabolic disorders, particularly in type 2 diabetes. However, its potential involvement in cardiovascular homeostasis remains unclear. This study aimed to investigate whether GULP1 attenuates DCM by preserving mitochondrial architecture and bioenergetic function, and to explore the underlying molecular mechanisms.

methodsCardiac-specific Gulp1 knockout (Gulp1KO) and overexpressing (Gulp1KI) mice, along with their wild-type littermates (Gulp1f/f, Gulp1WT), were fed a high-fat diet for 6 months to induce DCM. Cardiac function was assessed by echocardiography and hemodynamic measurements. Cardiac mitochondrial structure and function were evaluated using electron microscopy, enzyme activity assays, ATP production and fatty acid oxidation. Primary ventricular myocytes derived from neonatal and adult mice were employed to delineate the molecular and signaling mechanisms underlying GULP1-mediated protection against palmitic acid (PA)-induced mitochondrial morphological alterations and dysfunction.

resultsGULP1 expression was markedly reduced in myocardial tissues from DCM patients and mouse models. Cardiac-specific GULP1 overexpression significantly attenuated cardiac dysfunction, alleviated mitochondrial structural disruption and respiratory impairment in diabetes, while reducing oxidative stress and cardiomyocyte apoptosis. Mechanistically, GULP1 directly interacted with IKIP (inhibitor of nuclear factor κB kinase-interacting protein) to alleviate IKIP-mediated inhibition of IKKβ-dependent NF-κB activation. This interaction enhanced NF-κB signaling, upregulated OPA1 (optic atrophy 1) expression and restored mitochondrial morphology, while improving fatty acid metabolism in DCM hearts. Consistently, GULP1 prevented PA-induced mitochondrial dysfunction, oxidative stress, and cardiomyocyte apoptosis in vitro through the IKIP/NF-κB/OPA1 signaling axis.

conclusionsThe IKIP/NF-κB/OPA1 signaling axis constitutes an essential mechanism through which GULP1 preserves mitochondrial morphofunction, thereby translating into cardioprotection against diabetic cardiomyopathy. These results identify GULP1 as a compelling therapeutic target for DCM.

Indexed as

Adaptor Proteins, Signal TransducingDiabetic CardiomyopathiesI-kappa B KinaseMitochondria, HeartMyocytes, CardiacNF-kappa BAnimalsApoptosisCells, CulturedDisease Models, AnimalEnergy MetabolismGTP PhosphohydrolasesHumansMaleMice, Inbred C57BLMice, KnockoutAdaptor Proteins, Signal TransducingGTP PhosphohydrolasesI-kappa B KinaseNF-kappa BOpa1 protein, mouseDiabetic cardiomyopathyGULP1IKIPMitochondrial morphofunctionOPA1

Identifiers

PMID42015218
PMCPMC13235008

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.